The myelodysplastic syndrome as a prototypical epigenetic disease

Increased CDA Expression/Activity in Males Contributes to Decreased Cytidine Analog Half-Life and Likely Contributes to Worse Outcomes with 5-Azacytidine or Decitabine Therapy

(2013) R. Z. Mahfouz et al.   CLINICAL CANCER RESEARCH

Clinical Presentation, Diagnosis, and Prognosis of Myelodysplastic Syndromes

(2012) James M. Foran et al.   AMERICAN JOURNAL OF MEDICINE

Activating CBL mutations are associated with a distinct MDS/MPN phenotype

(2012) Juliana Schwaab et al.   ANNALS OF HEMATOLOGY

Defects in spliceosomal machinery: a new pathway of leukaemogenesis

(2012) Jaroslaw P. Maciejewski et al.   BRITISH JOURNAL OF HAEMATOLOGY

ASXL1 Mutations Promote Myeloid Transformation through Loss of PRC2-Mediated Gene Repression

(2012) Omar Abdel-Wahab et al.   CANCER CELL

DNA Methylation Does Not Stably Lock Gene Expression but Instead Serves as a Molecular Mark for Gene Silencing Memory

(2012) N. J.- M. Raynal et al.   CANCER RESEARCH

Tet family proteins and 5-hydroxymethylcytosine in development and disease

(2012) L. Tan et al.   DEVELOPMENT

Effects ofTET2mutations on DNA methylation in chronic myelomonocytic leukemia

(2012) Jumpei Yamazaki et al.   Epigenetics

Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis

(2012) Lambert Busque et al.   NATURE GENETICS

Understanding the language of Lys36 methylation at histone H3

(2012) Eric J. Wagner et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Argonaute proteins couple chromatin silencing to alternative splicing

(2012) Maya Ameyar-Zazoua et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27)

(2012) M. T. McCabe et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Tet2 Loss Leads to Increased Hematopoietic Stem Cell Self-Renewal and Myeloid Transformation

(2011) Kelly Moran-Crusio et al.   CANCER CELL

Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group

(2011) Michael Lübbert et al.   JOURNAL OF CLINICAL ONCOLOGY

Gene expression profiling in MDS and AML: potential and future avenues

(2011) K Theilgaard-Mönch et al.   LEUKEMIA

Recurrent DNMT3A mutations in patients with myelodysplastic syndromes

(2011) M J Walter et al.   LEUKEMIA

DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia

(2011) K H Metzeler et al.   LEUKEMIA

Increased methylation variation in epigenetic domains across cancer types

(2011) Kasper Daniel Hansen et al.   NATURE GENETICS

Epigenetic variation and cellular Darwinism

(2011) Jean-Pierre Issa   NATURE GENETICS

Dnmt3a is essential for hematopoietic stem cell differentiation

(2011) Grant A Challen et al.   NATURE GENETICS

Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia

(2011) Xiao-Jing Yan et al.   NATURE GENETICS

Mechanisms of Resistance to Decitabine in the Myelodysplastic Syndrome

(2011) Taichun Qin et al.   PLoS One

Profiling of histone H3 lysine 9 trimethylation levels predicts transcription factor activity and survival in acute myeloid leukemia

(2010) C. Muller-Tidow et al.   BLOOD

Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation

(2010) Maria E. Figueroa et al.   CANCER CELL

Distinctive microRNA expression profiles in CD34+ bone marrow cells from patients with myelodysplastic syndrome

(2010) Michaela Dostalova Merkerova et al.   EUROPEAN JOURNAL OF HUMAN GENETICS

Human aging-associated DNA hypermethylation occurs preferentially at bivalent chromatin domains

(2010) V. K. Rakyan et al.   GENOME RESEARCH

Widespread and tissue specific age-related DNA methylation changes in mice

(2010) S. Maegawa et al.   GENOME RESEARCH

Myelodysplastic Syndromes Classification and Risk Stratification

(2010) Rami S. Komrokji et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML

(2010) F Dicker et al.   LEUKEMIA

Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2

(2010) Myunggon Ko et al.   NATURE

Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes

(2010) Gorica Nikoloski et al.   NATURE GENETICS

DNMT3AMutations in Acute Myeloid Leukemia

(2010) Timothy J. Ley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Structure of DNMT1-DNA Complex Reveals a Role for Autoinhibition in Maintenance DNA Methylation

(2010) J. Song et al.   SCIENCE

Polycomb group protein-mediated repression of transcription

(2010) Lluís Morey et al.   TRENDS IN BIOCHEMICAL SCIENCES

Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies

(2009) T. E. Fandy et al.   BLOOD

MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation

(2009) M. E. Figueroa et al.   BLOOD

Histone deacetylase inhibitors as anti-neoplastic agents

(2009) Nicolas Batty et al.   CANCER LETTERS

Targeting DNA Methylation

(2009) J.-P. J. Issa et al.   CLINICAL CANCER RESEARCH

DNA Methylation Predicts Survival and Response to Therapy in Patients With Myelodysplastic Syndromes

(2009) Lanlan Shen et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

(2009) Pierre Fenaux et al.   LANCET ONCOLOGY

Human DNA methylomes at base resolution show widespread epigenomic differences

(2009) Ryan Lister et al.   NATURE

Acquired mutations in TET2 are common in myelodysplastic syndromes

(2009) Saskia M C Langemeijer et al.   NATURE GENETICS

A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q– syndrome

(2009) Jillian L Barlow et al.   NATURE MEDICINE

p53-Inducible Ribonucleotide Reductase (p53R2/RRM2B) Is a DNA Hypomethylation-Independent Decitabine Gene Target That Correlates with Clinical Response in Myelodysplastic Syndrome/Acute Myelogenous Leukemia

(2008) P. A. Link et al.   CANCER RESEARCH